Clinical trials: Vehicle, completed
Bacterial Conjunctivitis
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
- Trial name
- NCT01175590
- Testing
- Besivance, Vehicle
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- Bausch & Lomb Incorporated
Acne Vulgaris
A Study of S6G5T3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761810
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Allergic Contact Dermatitis
Bioequivalence of Ethylenediamine Dihydrochloride Study
The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.
- Trial name
- NCT01798589
- Testing
- Ethylenediamine dihydrochloride allergen patch
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Allerderm
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)
This Phase 3 study (Study 306) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT02368210
- Testing
- 122-0551 Foam, Vehicle Foam
- Where
- 8 sites in United States
- Volunteers
- 151 people
- Sponsor
- Therapeutics, Inc.
Psoriasis Vulgaris
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536886
- Testing
- LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle
- Where
- 39 sites in United States
- Volunteers
- 376 people
- Sponsor
- LEO Pharma
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon.
- Trial name
- NCT02688270
- Testing
- Vascana (0.9% nitroglycerin cream)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Covis Pharma S.à.r.l.
Acne Vulgaris
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its…
- Trial name
- NCT03307577
- Testing
- UHE-101 Cream, Vehicle Cream
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
The objectives of this study are to compare the efficacy and safety of DFD01 Spray to Vehicle Spray for topical treatment of moderate plaque psoriasis
- Trial name
- NCT01967069
- Testing
- DFD01 Spray, Vehicle Spray
- Where
- 28 sites in United States
- Volunteers
- 277 people
- Sponsor
- Primus Pharmaceuticals
Cataract
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery…
- Trial name
- NCT01426854
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle Ophthalmic Solution
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Alcon Research
COVID-19
The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers
Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.
- Trial name
- NCT04697654
- Testing
- TLC19, TLC19 Vehicle
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taiwan Liposome Company
Dry Eye
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.
- Trial name
- NCT00893139
- Testing
- AL-38583 ophthalmic solution 0.05%, AL-38583 ophthalmic solution 0.10%, AL-38583 vehicle
- Volunteers
- 765 people
- Sponsor
- Alcon Research
Desmoid, Desmoid Fibromatosis of Skin
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
In this study Drug-eluting microbeads (DEB) loaded with Doxorubicin will be delivered into the target Desmoid Fibromatoses (DF) tissue via selective arterial embolization by angiographic technique.
- Conditions
- Desmoid, Desmoid Fibromatosis of Skin, Desmoid Neoplasm of Chest Wall, Desmoid Tumor Caused by Somatic Mutation
- Trial name
- NCT03966742
- Testing
- Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Rabin Medical Center
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Psoriasis
Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test
Ciclosporin is a cyclic nonribosomal polypeptide of 11 amino acids produced by the fungi Tolypocladium inflatum and Cylindrocarpon lucidum.
- Trial name
- NCT00578370
- Testing
- Ciclosporin 0.5% (Formulation 01B), Ciclosporin 1.5% (Formulation 02B), 0.1% betamethasone
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- ISDIN
Healthy
Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.
This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.
- Trial name
- PRO-232 (NCT06352541)
- Testing
- PRO-232
- Where
- Mexico
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Pain, Acute Otitis Media
Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media
To assess the clinical safety and efficacy of the Benzocaine relative to placebo in pain relief associated with acute otitis media.
- Trial name
- NCT02092454
- Testing
- Benzocaine
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Otic Therapy, LLC
Surgery
Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects
Evaluate the effects of Chlorhexidine Gluconate (CHG) cloth on the reduction of bacteria on the skin.
- Trial name
- NCT02222896
- Testing
- Chlorhexidine Gluconate, Vehicle, DynaHex-2
- Where
- United States
- Volunteers
- 347 people, healthy volunteers welcome
- Sponsor
- Medline Industries
Actinic Keratosis
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
- Trial name
- NCT00852137
- Testing
- PEP005 (ingenol mebutate) Gel, 0.05%, Vehicle Gel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Peplin
Dry Eye Disease
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
- Trial name
- NCT05403827
- Testing
- K-161
- Where
- 51 sites in United States
- Volunteers
- 644 people
- Sponsor
- Kowa Research Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.